A photoactivable natural product with broad antiviral activity against enveloped viruses including highly pathogenic coronaviruses

Author:

Meunier Thomas1,Desmarets Lowiese1,Bordage Simon2,Bamba Moussa23,Hervouet Kévin1,Rouillé Yves1ORCID,François Nathan1,Decossas Marion4,Sencio Valentin1,Trottein François1ORCID,Tra Bi Fézan Honora3,Lambert Olivier4,Dubuisson Jean1ORCID,Belouzard Sandrine1,Sahpaz Sevser2,Séron Karin1ORCID

Affiliation:

1. Univ Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.

2. Univ Lille, Université de Liège, Université de Picardie Jules Verne, JUNIA, UMRT 1158 BioEcoAgro, Métabolites spécialisés d’origine végétale, F-59000 Lille, France.

3. UFR Sciences de la Nature, Université Nangui Abrogoua, BP 801 Abidjan 02, Côte d'Ivoire.

4. Univ Bordeaux, CBMN UMR 5248, Bordeaux INP, F-33600 Pessac, France.

Abstract

The SARS-CoV-2 outbreak has highlighted the need for broad-spectrum antivirals against coronaviruses (CoVs). Here, pheophorbide a (Pba) was identified as a highly active antiviral molecule against HCoV-229E after bioguided fractionation of plant extracts. The antiviral activity of Pba was subsequently shown for SARS-CoV-2 and MERS-CoV, and its mechanism of action was further assessed, showing that Pba is an inhibitor of coronavirus entry by directly targeting the viral particle. Interestingly, the antiviral activity of Pba depends on light exposure, and Pba was shown to inhibit virus-cell fusion by stiffening the viral membrane as demonstrated by cryo-electron microscopy. Moreover, Pba was shown to be broadly active against several other enveloped viruses, and reduced SARS-CoV-2 and MERS-CoV replication in primary human bronchial epithelial cells. Pba is the first described natural antiviral against SARS-CoV-2 with direct photosensitive virucidal activity that holds potential for COVID-19 therapy or disinfection of SARS-CoV-2 contaminated surfaces.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference202 articles.

1. Zhu N Zhang D Wang W Li X Yang B Song J Zhao X Huang B Shi W Lu R Niu P

2. 774 Zhan F Ma X Wang D Xu W Wu G Gao GF Tan W. 2020. A Novel Coronavirus from

3. 775 Patients with Pneumonia in China , 2019 . N Engl J Med 382 : 727 - 733 .

4. 776

5. Huang C Wang Y Li X Ren L Zhao J Hu Y Zhang L Fan G Xu J Gu X Cheng Z Yu

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3